Physician

Abaid Ullah Anwar Choudry, MD

According to 2025 Medicare claims, Abaid Choudry, MD (NPI: 1235246588) practices internal medicine in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Hudson, NJ. This provider's primary affiliated billing organization is SAHARA MEDICAL ASSOCIATES, PC (NPI: 1528117827; TIN: 200232291) and primary practice location at 07306-5531.

Choudry's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 102 traditional Medicare patients, billed 638 HCPCS/CPT codes, and received $34,373 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 5,027 prescription claims across 382 beneficiaries totaling $1,311,727 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 17 claims. Open Payments data shows 8 records totaling $127. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $51,754 and ending at $34,373. Concurrently, Part D prescription costs have risen steadily, from $348,506 to $1,311,727. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $1,867 to $5,304.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	137	827	$51,754
2016	127	808	$44,886
2017	132	934	$48,535
2018	124	746	$37,688
2019	116	742	$37,165
2020	104	560	$30,248
2021	116	745	$52,259
2022	108	655	$40,137
2023	103	620	$31,663
2024	102	638	$34,373

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	4,770	$348,506
2016	182	5,290	$637,592
2017	186	5,913	$1,265,004
2018	194	6,091	$1,115,752
2019	230	6,441	$1,049,806
2020	215	5,261	$1,162,555
2021	238	3,804	$1,040,378
2022	342	4,743	$1,418,088
2023	362	4,638	$1,405,391
2024	382	5,027	$1,311,727

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	47	135	$1,410
2016	47	90	$858
2017	30	126	$1,308
2018	28	116	$1,500
2019	14	130	$16,705
2020	N/R	97	$16,708
2021	N/R	145	$4,077
2022	N/R	98	$4,145
2023	N/R	34	$4,342
2024	N/R	17	$85

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	41	62	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	65	128	$78
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	76	175	$60
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	29	36	$28
36415	Insertion of needle into vein for collection of blood sample	40	60	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	101	6,500	$120,457
Janumet	Sitagliptin Phos/Metformin Hcl	99	6,560	$114,572
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	58	4,110	$99,333
Jardiance	Empagliflozin	84	4,710	$90,461
Linzess	Linaclotide	75	4,630	$80,239

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	17	$85

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$127	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abaid Ullah Anwar Choudry, MD?

Tedicare shows public-source Medicare data for Abaid Ullah Anwar Choudry, MD (NPI 1235246588), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abaid Ullah Anwar Choudry, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Abaid Ullah Anwar Choudry, MD?

Abaid Ullah Anwar Choudry, MD is linked to SAHARA MEDICAL ASSOCIATES, PC (billing NPI 1528117827) in the available physician profile data.

Does Abaid Ullah Anwar Choudry, MD have Open Payments data?

Abaid Ullah Anwar Choudry, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.